vs
ANI PHARMACEUTICALS INC（ANIP）与MARCUS CORP（MCS）财务数据对比。点击上方公司名可切换其他公司
ANI PHARMACEUTICALS INC的季度营收约是MARCUS CORP的1.3倍（$247.1M vs $193.5M），ANI PHARMACEUTICALS INC同比增速更快（29.6% vs 2.8%），ANI PHARMACEUTICALS INC自由现金流更多（$29.1M vs $26.4M），过去两年ANI PHARMACEUTICALS INC的营收复合增速更高（34.1% vs 18.2%）
ANI制药是一家总部位于美国的特种制药企业，专注于研发、生产和销售仿制药及品牌处方药，核心产品覆盖皮肤科、肿瘤、中枢神经系统治疗、抗感染等领域，主要服务美国境内的医疗机构、零售药房和患者群体。
马库斯公司是一家美国企业，主营商业地产领域相关服务，业务覆盖美国与加拿大，提供商业地产经纪、按揭经纪、行业研究以及咨询服务，首创了由单一经纪公司独家代理房源挂牌的行业模式，目前在美加两国设有超过80家办公室，拥有员工超1800名。
ANIP vs MCS — 直观对比
营收规模更大
ANIP
是对方的1.3倍
$193.5M
营收增速更快
ANIP
高出26.9%
2.8%
自由现金流更多
ANIP
多$2.7M
$26.4M
两年增速更快
ANIP
近两年复合增速
18.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $247.1M | $193.5M |
| 净利润 | $27.5M | — |
| 毛利率 | — | — |
| 营业利润率 | 14.1% | 0.9% |
| 净利率 | 11.1% | — |
| 营收同比 | 29.6% | 2.8% |
| 净利润同比 | 367.5% | — |
| 每股收益（稀释后） | $1.14 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANIPMCS
| Q4 25 | $247.1M | $193.5M | ||
| Q3 25 | $227.8M | $210.2M | ||
| Q2 25 | $211.4M | $206.0M | ||
| Q1 25 | $197.1M | $148.8M | ||
| Q4 24 | $190.6M | $188.3M | ||
| Q3 24 | $148.3M | $232.7M | ||
| Q2 24 | $138.0M | $176.0M | ||
| Q1 24 | $137.4M | $138.5M |
净利润ANIPMCS
| Q4 25 | $27.5M | — | ||
| Q3 25 | $26.6M | $16.2M | ||
| Q2 25 | $8.5M | $7.3M | ||
| Q1 25 | $15.7M | $-16.8M | ||
| Q4 24 | $-10.3M | $986.0K | ||
| Q3 24 | $-24.2M | $23.3M | ||
| Q2 24 | $-2.3M | $-20.2M | ||
| Q1 24 | $18.2M | $-11.9M |
营业利润率ANIPMCS
| Q4 25 | 14.1% | 0.9% | ||
| Q3 25 | 15.9% | 10.8% | ||
| Q2 25 | 6.6% | 6.3% | ||
| Q1 25 | 13.3% | -13.7% | ||
| Q4 24 | -2.3% | -1.2% | ||
| Q3 24 | -13.8% | 14.1% | ||
| Q2 24 | 3.7% | 1.3% | ||
| Q1 24 | 14.8% | -12.0% |
净利率ANIPMCS
| Q4 25 | 11.1% | — | ||
| Q3 25 | 11.7% | 7.7% | ||
| Q2 25 | 4.0% | 3.6% | ||
| Q1 25 | 8.0% | -11.3% | ||
| Q4 24 | -5.4% | 0.5% | ||
| Q3 24 | -16.3% | 10.0% | ||
| Q2 24 | -1.7% | -11.5% | ||
| Q1 24 | 13.2% | -8.6% |
每股收益（稀释后）ANIPMCS
| Q4 25 | $1.14 | — | ||
| Q3 25 | $1.13 | — | ||
| Q2 25 | $0.36 | — | ||
| Q1 25 | $0.69 | — | ||
| Q4 24 | $-0.45 | — | ||
| Q3 24 | $-1.27 | — | ||
| Q2 24 | $-0.14 | — | ||
| Q1 24 | $0.82 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $285.6M | $23.4M |
| 总债务越低越好 | — | $159.0M |
| 股东权益账面价值 | $540.7M | $457.4M |
| 总资产 | $1.4B | $1.0B |
| 负债/权益比越低杠杆越低 | — | 0.35× |
8季度趋势，按日历期对齐
现金及短期投资ANIPMCS
| Q4 25 | $285.6M | $23.4M | ||
| Q3 25 | $262.6M | $7.4M | ||
| Q2 25 | $217.8M | $14.9M | ||
| Q1 25 | $149.8M | $11.9M | ||
| Q4 24 | $144.9M | $40.8M | ||
| Q3 24 | $145.0M | $28.4M | ||
| Q2 24 | $240.1M | $32.8M | ||
| Q1 24 | $228.6M | $17.3M |
总债务ANIPMCS
| Q4 25 | — | $159.0M | ||
| Q3 25 | — | $162.0M | ||
| Q2 25 | — | $179.9M | ||
| Q1 25 | — | $198.9M | ||
| Q4 24 | — | $159.1M | ||
| Q3 24 | — | $173.1M | ||
| Q2 24 | — | $175.7M | ||
| Q1 24 | — | $169.8M |
股东权益ANIPMCS
| Q4 25 | $540.7M | $457.4M | ||
| Q3 25 | $505.8M | $454.3M | ||
| Q2 25 | $436.8M | $448.4M | ||
| Q1 25 | $418.6M | $441.8M | ||
| Q4 24 | $403.7M | $464.9M | ||
| Q3 24 | $405.9M | $462.3M | ||
| Q2 24 | $455.8M | $449.4M | ||
| Q1 24 | $452.0M | $459.3M |
总资产ANIPMCS
| Q4 25 | $1.4B | $1.0B | ||
| Q3 25 | $1.4B | $1.0B | ||
| Q2 25 | $1.3B | $1.0B | ||
| Q1 25 | $1.3B | $1.0B | ||
| Q4 24 | $1.3B | $1.0B | ||
| Q3 24 | $1.3B | $1.0B | ||
| Q2 24 | $920.8M | $1.1B | ||
| Q1 24 | $914.5M | $1.0B |
负债/权益比ANIPMCS
| Q4 25 | — | 0.35× | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.40× | ||
| Q1 25 | — | 0.45× | ||
| Q4 24 | — | 0.34× | ||
| Q3 24 | — | 0.37× | ||
| Q2 24 | — | 0.39× | ||
| Q1 24 | — | 0.37× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $30.4M | $48.8M |
| 自由现金流经营现金流 - 资本支出 | $29.1M | $26.4M |
| 自由现金流率自由现金流/营收 | 11.8% | 13.6% |
| 资本支出强度资本支出/营收 | 0.5% | 11.6% |
| 现金转化率经营现金流/净利润 | 1.10× | — |
| 过去12个月自由现金流最近4个季度 | $171.4M | $989.0K |
8季度趋势，按日历期对齐
经营现金流ANIPMCS
| Q4 25 | $30.4M | $48.8M | ||
| Q3 25 | $44.1M | $39.1M | ||
| Q2 25 | $75.8M | $31.6M | ||
| Q1 25 | $35.0M | $-35.3M | ||
| Q4 24 | $15.9M | $52.6M | ||
| Q3 24 | $12.5M | $30.5M | ||
| Q2 24 | $17.4M | $36.0M | ||
| Q1 24 | $18.3M | $-15.1M |
自由现金流ANIPMCS
| Q4 25 | $29.1M | $26.4M | ||
| Q3 25 | $38.0M | $18.2M | ||
| Q2 25 | $71.8M | $14.7M | ||
| Q1 25 | $32.5M | $-58.3M | ||
| Q4 24 | $13.5M | $27.1M | ||
| Q3 24 | $7.7M | $12.0M | ||
| Q2 24 | $13.0M | $16.1M | ||
| Q1 24 | $13.7M | $-30.5M |
自由现金流率ANIPMCS
| Q4 25 | 11.8% | 13.6% | ||
| Q3 25 | 16.7% | 8.7% | ||
| Q2 25 | 34.0% | 7.1% | ||
| Q1 25 | 16.5% | -39.2% | ||
| Q4 24 | 7.1% | 14.4% | ||
| Q3 24 | 5.2% | 5.2% | ||
| Q2 24 | 9.4% | 9.2% | ||
| Q1 24 | 10.0% | -22.0% |
资本支出强度ANIPMCS
| Q4 25 | 0.5% | 11.6% | ||
| Q3 25 | 2.7% | 9.9% | ||
| Q2 25 | 1.9% | 8.2% | ||
| Q1 25 | 1.3% | 15.5% | ||
| Q4 24 | 1.3% | 13.5% | ||
| Q3 24 | 3.2% | 7.9% | ||
| Q2 24 | 3.2% | 11.3% | ||
| Q1 24 | 3.3% | 11.1% |
现金转化率ANIPMCS
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | 2.41× | ||
| Q2 25 | 8.87× | 4.32× | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | 53.31× | ||
| Q3 24 | — | 1.31× | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.00× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
MCS
| Theatres | $123.1M | 64% |
| Concessions | $51.0M | 26% |
| Food And Beverage | $21.2M | 11% |
